CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 139 enrolled
Drug / intervention
Canagliflozin (TA-7284) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02622113
NCT02622113Phase 4Completed
CompareCT.gov

An Open-Label, Multicenter Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Canagliflozin (TA-7284) as add-on to Insulin in Subjects With Type 2 Diabetes Mellitus

Tanabe Pharma Corporation·interventional·Posted Dec 4, 2015·Updated Jan 8, 2026

In Brief

A Phase 4 clinical trial evaluating Canagliflozin (TA-7284) and Insulin for Type 2 Diabetes Mellitus. Completed, enrolled 139 participants across 7 sites.

Detailed Summary

This extension study was designed to evaluate the safety and efficacy of Canagliflozin (TA-7284) in combination with Insulin in patients with type 2 Diabetes Mellitus. The extension study was an extension to double-blind study of 16 weeks (TA-7284-11)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesJapan
Collaborators--

Timeline

Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 4, 2015
Enrollment StartDec 1, 2014
Primary CompletionApr 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 10.6 years ago

Interventions

Canagliflozin (TA-7284)drug

The patients will receive Canagliflozin orally for 36 weeks

Insulindrug